On this World AIDS Day we are filled with both hope and concern.
Hope because significant progress has been made towards universal access. New HIV infections have dropped. Fewer children are born with HIV. And more than 4 million people are on treatment.
Concern because 28 years into the epidemic the virus continues to make inroads into new populations; stigma and discrimination continue to undermine efforts to turn back the epidemic. The violation of human rights of people living with HIV, women and girls, men who have sex with men, injecting drug users and sex workers must end.
UN Secretary-General Ban Ki-moon has called on "all countries to live up to their commitments to enact or enforce legislation outlawing discrimination against people living with HIV and members of vulnerable groups". On this World AIDS Day, let us work urgently to remove punitive laws and practices and put an end to discrimination against and criminalization of people affected by HIV.
On World AIDS Day let us also act on HIV prevention. For every two people put on treatment, five are newly infected. Too often prevention programmes are not reaching those most in need.
We can eliminate mother-to-child transmission of HIV. We can empower young people to protect themselves from HIV. We can stop violence against women and girls. We can protect drug users from becoming infected with HIV. And we can reduce sexual transmission of HIV.
Gains made today are fragile and must be sustained. The economic crisis should not be a reason for reducing investments in health. Economic adjustments must be made through a human rights lens that keeps the focus on those most vulnerable. This is the time to increase rather than decrease funding for AIDS.
AIDS provides a powerful mechanism for creating integrated health, human rights and development programmes. We must take AIDS out of isolation and create a broad social movement that will accelerate progress toward the Millennium Development Goals.
World AIDS Day provides an opportunity for all of us - individuals, communities and political leaders - to take action towards making universal access a reality.
Michel Sidibé, Executive Director of UNAIDS.
Business & Industry
- Sanofi’s venglustat earns Breakthrough Therapy designation in the US for type 3 Gaucher disease
- Abbott and Real Madrid launch nationwide effort to build the next 'Abbott Dream Team'
- Pfizer's Phase 2 study of trispecific antibody positive in moderate to severe atopic dermatitis
- U.S. FDA grants full approval to Pfizer's BRAFTOVI combination regimen in first-line metastatic colorectal cancer
- Pfizer launches cost savings program on TrumpRx lowering drug costs for millions of Americans
Research & Development
- A pioneering drug capable of reversing cognitive decline in Alzheimer’s disease in animal models
- Plastic bottles transformed into Parkinson’s drug using bacteria
- Researchers break decades-old bottleneck in chemotherapy drug manufacturing
- Preclinical study reveals new cream may prevent or slow growth of some common skin cancers
- Safer blood clot treatment with apixaban than with rivaroxaban
- Experimental chemo drug may trick the immune system into fighting cancer
- New drug combination doubles down on Alzheimer's treatments
Conferences & Events
- SAE Media Group proudly presents the 4th Annual AI in Drug Discovery Conference
- SAE Media Group's 6th annual 3D Cell Culture Conference
- CPHI Frankfurt returns to pre-pandemic strength as pharma industry booms again
- 14th Annual RNA Therapeutics: Investigating the next generation of genetic medicine through RNA based therapies
- CPHI Excellence in Pharma Award Winners 2022
- CPHI Frankfurt Report predicts huge funding overhang to drive contract services growth
- CPHI Frankfurt 2022: Global pharma confidence hits record high in the annual CPHI Pharma Index
Regulatory Affairs
- FDA expands artificial intelligence capabilities with agentic AI deployment
- FDA approves first gene therapy for treatment of aromatic L-amino acid decarboxylase deficiency
- FDA approves new treatment for hemophilia A or B
- FDA approves nasal spray influenza vaccine for self- or caregiver-administration
- FDA approves first nasal spray for treatment of anaphylaxis